Invitae - Invitae study shows therapy informed by genetic testing
https://ir.invitae.com/news-and-events/press-releases/press-release-details/2022/Invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy/default.aspx
WEBSAN FRANCISCO, Oct. 31, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the findings of a study that documents the actions clinicians take upon receiving a positive diagnostic genetic testing result for patients with epilepsy.
DA: 27 PA: 87 MOZ Rank: 69 Up or Down: Up